Epstein-Barr virus post-transplant lymphoproliferative disease (PTLD) after hematopoietic stem cell transplantation

被引：24

作者：

Ru, Yuhua ^{[1
,2
]}

Chen, Jia ^{[1
,2
]}

Wu, Depei ^{[1
,2
]}

机构：

[1] Soochow Univ, Affiliated Hosp 1, Jiangsu Inst Hematol, Suzhou 215006, Peoples R China

[2] Soochow Univ, Collaborat Innovat Ctr Hematol, Inst Blood & Marrow Transplantat, Suzhou 215006, Peoples R China

来源：

EUROPEAN JOURNAL OF HAEMATOLOGY | 2018年 / 101卷 / 03期

基金：

美国国家科学基金会; 国家重点研发计划;

关键词：

EB virus; hematopoietic stem cell transplantation; lymphoproliferative disease; BONE-MARROW-TRANSPLANTATION; EBV REACTIVATION; RISK-FACTORS; VIRAL LOAD; PREEMPTIVE RITUXIMAB; PROLONGED HYPOGAMMAGLOBULINEMIA; ALLOGENEIC TRANSPLANTATION; HEART-TRANSPLANTATION; EUROPEAN CONFERENCE; PEDIATRIC-PATIENTS;

D O I：

10.1111/ejh.13131

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Epstein-Barr virus (EBV) viremia and post-transplant lymphoproliferative disease (PTLD) are severe complications after hematopoietic stem cell transplantation (HSCT). A series of risk factors have been found to predict EBV viremia and PTLD, including the T-cell depletion, reduced intensity conditioning, and alternative donor. The rituximab pre-emptive therapy could improve PTLD prognosis significantly, but the trigger of initiating rituximab pre-emptive therapy has not been well established. Additionally, EBV-specific cytotoxic T cell (CTL) is a promising approach to treat EBV-PTLD.

引用

页码：283 / 290

页数：8

共 77 条

[1]

Abedi MR, 1997, INT J CANCER, V71, P624, DOI 10.1002/(SICI)1097-0215(19970516)71:4<624::AID-IJC19>3.0.CO

[2]

2-B

[3] Preemptive Management of Epstein-Barr Virus Reactivation After Hematopoietic Stem-Cell Transplantation [J].

Ahmad, Imran ;

Cau, Nguyen V. ;

Kwan, John ;

Maaroufi, Younes ;

Meuleman, Nathalie ;

Aoun, Mickael ;

Lewalle, Philippe ;

Martiat, Philippe ;

Crokaert, Francoise ;

Bron, Dominique .

TRANSPLANTATION, 2009, 87 (08) :1240-1245

[4] Controlled Epstein-Barr virus reactivation after allogeneic transplantation is associated with improved survival [J].

Auger, Sophie ;

Orsini, Mattea ;

Ceballos, Patrice ;

Fegueux, Nathalie ;

Kanouni, Tarik ;

Caumes, Bastien ;

Klein, Bernard ;

Villalba, Martin ;

Rossi, Jean-Francois .

EUROPEAN JOURNAL OF HAEMATOLOGY, 2014, 92 (05) :421-428

[5] Infectious mononucleosis [J].

Balfou, Henry H., Jr. ;

Dunmire, Samantha K. ;

Hogquist, Kristin A. .

CLINICAL & TRANSLATIONAL IMMUNOLOGY, 2015, 4

[6]

Bao Xiebing, 2016, Zhonghua Xue Ye Xue Za Zhi, V37, P138, DOI 10.3760/cma.j.issn.0253-2727.2016.02.011

[7] Low incidence of Epstein-Barr virus-associated posttransplantation lymphoproliferative disorders in 272 unrelated-donor umbilical cord blood transplant recipients [J].

Barker, JN ;

Martin, PL ;

Coad, JE ;

DeFor, T ;

Trigg, ME ;

Kurtzberg, J ;

Weisdorf, DJ ;

Wagner, JE .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2001, 7 (07) :395-399

[8] Incidence, kinetics, and risk factors of Epstein-Barr virus viremia in pediatric patients after allogeneic stem cell transplantation [J].

Bordon, Victoria ;

Padalko, Elizaveta ;

Benoit, Yves ;

Dhooge, Catharina ;

Laureys, Genevieve .

PEDIATRIC TRANSPLANTATION, 2012, 16 (02) :144-150

[9]

Burke Lora E, 2003, J Cardiovasc Nurs, V18, P256

[10] Greatly reduced risk of EBV reactivation in rituximab-experienced recipients of alemtuzumab-conditioned allogeneic HSCT [J].

Burns, D. M. ;

Rana, S. ;

Martin, E. ;

Nagra, S. ;

Ward, J. ;

Osman, H. ;

Bell, A. I. ;

Moss, P. ;

Russell, N. H. ;

Craddock, C. F. ;

Fox, C. P. ;

Chaganti, S. .

BONE MARROW TRANSPLANTATION, 2016, 51 (06) :825-832

← 1 2 3 4 5 6 7 8 →